These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

149 related articles for article (PubMed ID: 17640780)

  • 41. Heterologous MVA-S prime Ad5-S boost regimen induces high and persistent levels of neutralizing antibody response against SARS coronavirus.
    Ba L; Yi CE; Zhang L; Ho DD; Chen Z
    Appl Microbiol Biotechnol; 2007 Oct; 76(5):1131-6. PubMed ID: 17581748
    [TBL] [Abstract][Full Text] [Related]  

  • 42. ChAdOx1-S adenoviral vector vaccine applied intranasally elicits superior mucosal immunity compared to the intramuscular route of vaccination.
    Cokarić Brdovčak M; Materljan J; Šustić M; Ravlić S; Ružić T; Lisnić B; Miklić K; Brizić I; Pribanić Matešić M; Juranić Lisnić V; Halassy B; Rončević D; Knežević Z; Štefan L; Bertoglio F; Schubert M; Čičin-Šain L; Markotić A; Jonjić S; Krmpotić A
    Eur J Immunol; 2022 Jun; 52(6):936-945. PubMed ID: 35304741
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Neutralizing antibody against severe acute respiratory syndrome (SARS)-coronavirus spike is highly effective for the protection of mice in the murine SARS model.
    Ishii K; Hasegawa H; Nagata N; Ami Y; Fukushi S; Taguchi F; Tsunetsugu-Yokota Y
    Microbiol Immunol; 2009 Feb; 53(2):75-82. PubMed ID: 19291090
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Intranasal immunization with plasmid DNA encoding spike protein of SARS-coronavirus/polyethylenimine nanoparticles elicits antigen-specific humoral and cellular immune responses.
    Shim BS; Park SM; Quan JS; Jere D; Chu H; Song MK; Kim DW; Jang YS; Yang MS; Han SH; Park YH; Cho CS; Yun CH
    BMC Immunol; 2010 Dec; 11():65. PubMed ID: 21194475
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Complete protection against severe acute respiratory syndrome coronavirus-mediated lethal respiratory disease in aged mice by immunization with a mouse-adapted virus lacking E protein.
    Fett C; DeDiego ML; Regla-Nava JA; Enjuanes L; Perlman S
    J Virol; 2013 Jun; 87(12):6551-9. PubMed ID: 23576515
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Immunogenicity of a receptor-binding domain of SARS coronavirus spike protein in mice: implications for a subunit vaccine.
    Zakhartchouk AN; Sharon C; Satkunarajah M; Auperin T; Viswanathan S; Mutwiri G; Petric M; See RH; Brunham RC; Finlay BB; Cameron C; Kelvin DJ; Cochrane A; Rini JM; Babiuk LA
    Vaccine; 2007 Jan; 25(1):136-43. PubMed ID: 16919855
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Inactivated SARS-CoV vaccine elicits high titers of spike protein-specific antibodies that block receptor binding and virus entry.
    He Y; Zhou Y; Siddiqui P; Jiang S
    Biochem Biophys Res Commun; 2004 Dec; 325(2):445-52. PubMed ID: 15530413
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Effect of mucosal and systemic immunization with virus-like particles of severe acute respiratory syndrome coronavirus in mice.
    Lu B; Huang Y; Huang L; Li B; Zheng Z; Chen Z; Chen J; Hu Q; Wang H
    Immunology; 2010 Jun; 130(2):254-61. PubMed ID: 20406307
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Identification of immunodominant sites on the spike protein of severe acute respiratory syndrome (SARS) coronavirus: implication for developing SARS diagnostics and vaccines.
    He Y; Zhou Y; Wu H; Luo B; Chen J; Li W; Jiang S
    J Immunol; 2004 Sep; 173(6):4050-7. PubMed ID: 15356154
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Protection against EHV-1 challenge infection in the murine model after vaccination with various formulations of recombinant glycoprotein gp14 (gB).
    Osterrieder N; Wagner R; Brandmüller C; Schmidt P; Wolf H; Kaaden OR
    Virology; 1995 Apr; 208(2):500-10. PubMed ID: 7747423
    [TBL] [Abstract][Full Text] [Related]  

  • 51. A novel intranasal Protollin-based measles vaccine induces mucosal and systemic neutralizing antibody responses and cell-mediated immunity in mice.
    Chabot S; Brewer A; Lowell G; Plante M; Cyr S; Burt DS; Ward BJ
    Vaccine; 2005 Feb; 23(11):1374-83. PubMed ID: 15661386
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Neutralizing antibody and protective immunity to SARS coronavirus infection of mice induced by a soluble recombinant polypeptide containing an N-terminal segment of the spike glycoprotein.
    Bisht H; Roberts A; Vogel L; Subbarao K; Moss B
    Virology; 2005 Apr; 334(2):160-5. PubMed ID: 15780866
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rhabdovirus-based vaccine platforms against henipaviruses.
    Kurup D; Wirblich C; Feldmann H; Marzi A; Schnell MJ
    J Virol; 2015 Jan; 89(1):144-54. PubMed ID: 25320306
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Immunogenicity of the spike glycoprotein of bat SARS-like coronavirus.
    Hou YX; Peng C; Han ZG; Zhou P; Chen JG; Shi ZL
    Virol Sin; 2010 Feb; 25(1):36-44. PubMed ID: 20960282
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Identification of a critical neutralization determinant of severe acute respiratory syndrome (SARS)-associated coronavirus: importance for designing SARS vaccines.
    He Y; Zhu Q; Liu S; Zhou Y; Yang B; Li J; Jiang S
    Virology; 2005 Mar; 334(1):74-82. PubMed ID: 15749124
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Effects of different immunization protocols and adjuvant on antibody responses to inactivated SARS-CoV vaccine.
    Gai W; Zou W; Lei L; Luo J; Tu H; Zhang Y; Wang K; Tien P; Yan H
    Viral Immunol; 2008 Mar; 21(1):27-37. PubMed ID: 18355120
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Development and characterization of a severe acute respiratory syndrome-associated coronavirus-neutralizing human monoclonal antibody that provides effective immunoprophylaxis in mice.
    Greenough TC; Babcock GJ; Roberts A; Hernandez HJ; Thomas WD; Coccia JA; Graziano RF; Srinivasan M; Lowy I; Finberg RW; Subbarao K; Vogel L; Somasundaran M; Luzuriaga K; Sullivan JL; Ambrosino DM
    J Infect Dis; 2005 Feb; 191(4):507-14. PubMed ID: 15655773
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Identification of murine CD8 T cell epitopes in codon-optimized SARS-associated coronavirus spike protein.
    Zhi Y; Kobinger GP; Jordan H; Suchma K; Weiss SR; Shen H; Schumer G; Gao G; Boyer JL; Crystal RG; Wilson JM
    Virology; 2005 Apr; 335(1):34-45. PubMed ID: 15823604
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Intranasal inoculation of an MVA-based vaccine induces IgA and protects the respiratory tract of hACE2 mice from SARS-CoV-2 infection.
    Americo JL; Cotter CA; Earl PL; Liu R; Moss B
    Proc Natl Acad Sci U S A; 2022 Jun; 119(24):e2202069119. PubMed ID: 35679343
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Identification of two neutralizing regions on the severe acute respiratory syndrome coronavirus spike glycoprotein produced from the mammalian expression system.
    Wang S; Chou TH; Sakhatskyy PV; Huang S; Lawrence JM; Cao H; Huang X; Lu S
    J Virol; 2005 Feb; 79(3):1906-10. PubMed ID: 15650214
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.